MX9707613A - Citostaticos modificados con hidratos de carbono. - Google Patents

Citostaticos modificados con hidratos de carbono.

Info

Publication number
MX9707613A
MX9707613A MX9707613A MX9707613A MX9707613A MX 9707613 A MX9707613 A MX 9707613A MX 9707613 A MX9707613 A MX 9707613A MX 9707613 A MX9707613 A MX 9707613A MX 9707613 A MX9707613 A MX 9707613A
Authority
MX
Mexico
Prior art keywords
sugar
cytostatics
modified
modified cytostatics
modification
Prior art date
Application number
MX9707613A
Other languages
English (en)
Inventor
Hans-Georg Lerchen
Karsten Von Dem Bruch
Uwe Petersen
Jorg Baumgarten
Norbert Piel
Horst Peter Antonicek
Walter Weichel
Michael Sperzel
Klaus Dieter Bremm
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX9707613A publication Critical patent/MX9707613A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invencion se refiere a citostáticos que mediante modificacion con azucares son específicos de tumores. Espaciadores adecuados garantizan la estabilidad en suero y, simultáneamente, la actividad intracelular.
MX9707613A 1995-04-04 1996-03-22 Citostaticos modificados con hidratos de carbono. MX9707613A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19512484A DE19512484A1 (de) 1995-04-04 1995-04-04 Kohlenhydratmodifizierte Cytostatika
PCT/EP1996/001279 WO1996031532A1 (de) 1995-04-04 1996-03-22 Kohlenhydratmodifizierte cytostatika

Publications (1)

Publication Number Publication Date
MX9707613A true MX9707613A (es) 1997-12-31

Family

ID=7758679

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9707613A MX9707613A (es) 1995-04-04 1996-03-22 Citostaticos modificados con hidratos de carbono.

Country Status (27)

Country Link
US (1) US6271342B1 (es)
EP (1) EP0819135B1 (es)
JP (1) JPH11502860A (es)
KR (1) KR19980703591A (es)
CN (1) CN1185786A (es)
AT (1) ATE186738T1 (es)
AU (1) AU713466B2 (es)
BG (1) BG63048B1 (es)
BR (1) BR9604825A (es)
CA (1) CA2217164A1 (es)
CZ (1) CZ291098B6 (es)
DE (2) DE19512484A1 (es)
DK (1) DK0819135T3 (es)
EE (1) EE03619B1 (es)
ES (1) ES2140078T3 (es)
GR (1) GR3032605T3 (es)
HU (1) HUP9800513A3 (es)
IS (1) IS1822B (es)
MX (1) MX9707613A (es)
NO (1) NO974564L (es)
NZ (1) NZ305855A (es)
PL (1) PL183574B1 (es)
RU (1) RU2170234C2 (es)
SK (1) SK281785B6 (es)
TW (1) TW384290B (es)
UA (1) UA61054C2 (es)
WO (1) WO1996031532A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4459297A (en) * 1996-09-30 1998-04-24 Bayer Aktiengesellschaft Glycoconjugates from modified camptothecin derivates (20-o-linkage)
DE19640970A1 (de) * 1996-10-04 1998-04-16 Bayer Ag Modifizierte Cytostatika
JP3101710B2 (ja) 1997-02-28 2000-10-23 工業技術院長 硫酸化オリゴ糖化合物
ID23424A (id) * 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
ATE423776T1 (de) 1997-09-15 2009-03-15 Procter & Gamble Antimikrobielle chinolone, ihre zusammensetzungen und ihre verwendungen
US6387928B1 (en) 1997-09-15 2002-05-14 The Procter & Gamble Co. Antimicrobial quinolones, their compositions and uses
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
DE10005275A1 (de) * 2000-02-07 2001-08-09 Bayer Ag Neuartige Glycokonjugate
US7220824B1 (en) * 2000-08-28 2007-05-22 Bayer Aktiengesellschaft Integrin-mediated drug targeting
EP1219634A1 (en) * 2000-12-27 2002-07-03 Bayer Aktiengesellschaft Cytostatic-glycoconjugates having specifically cleavable peptidic linking units
EP1238678A1 (en) * 2001-03-08 2002-09-11 Bayer Aktiengesellschaft Enzyme-activated cytostatic conjugates with integrin ligands
US20050037423A1 (en) * 2001-11-09 2005-02-17 Bayer Healthcare Ag Isotopycally coded affinity marker 2
US7199149B2 (en) * 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
KR100956913B1 (ko) 2003-12-19 2010-05-11 제넨테크, 인크. 치료제로서 유용한 일가 항체 단편
PT2001862E (pt) 2006-03-28 2011-07-20 Warner Chilcott Co Llc Sais de malato e polimorfos do ácido (3s,5s)-7-[3- amino-5-metil-piperidinil]-1-ciclopropil-1,4-dihidro- 8-metoxi-4-oxo-3-quinolinocarboxílico
WO2007110836A1 (en) 2006-03-28 2007-10-04 The Procter & Gamble Company A hydride reduction process for preparing quinolone intermediates
BRPI0709220A2 (pt) 2006-03-28 2011-07-12 Procter & Gamble processo de acoplamento para preparo de intermediários de quinolona
WO2016109880A1 (en) 2015-01-06 2016-07-14 Immunovaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
EP3380126A4 (en) * 2015-11-25 2019-07-24 LegoChem Biosciences, Inc. ANTIBODY-ACTIVE CONJUGATES WITH BRANCHED LINKERS AND ASSOCIATED METHODS
CA3006242A1 (en) 2015-11-25 2017-06-01 Legochem Biosciences, Inc. Conjugates comprising self-immolative groups and methods related thereto
AU2018246806B2 (en) 2017-03-29 2022-05-12 Ligachem Biosciences Inc. Pyrrolobenzodiazepine dimer precursor and ligand-linker conjugate compound thereof
CA3099680A1 (en) 2018-05-09 2019-11-14 Legochem Biosciences, Inc. Compositions and methods related to anti-cd19 antibody drug conjugates
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
JP7820508B2 (ja) * 2021-10-06 2026-02-25 サムヤン コーポレイション 飽和フロジオキシン誘導体化合物及びその二次電池用添加剤としての使用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5977356A (ja) * 1982-06-30 1984-05-02 Fuji Photo Film Co Ltd 螢光アツセイ用多層分析要素およびそれを用いる螢光アツセイ法
DE3611194A1 (de) 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
EP0284071B1 (en) * 1987-03-26 1994-06-08 Neorx Corporation Metal-radionuclide-labeled proteins and glycoproteins for diagnosis and therapy
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4980343A (en) * 1988-10-27 1990-12-25 Bayer Aktiengesellschaft Aminooxodihydroisoindoloquinazoline carcinostatic agents
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
CA2031803C (en) * 1989-12-13 2001-05-29 Ramakrishnan Nagarajan Improvements in or relating to glycopeptide deriveratives
US5160727A (en) * 1990-02-13 1992-11-03 Warner-Lambert Company Tumor cell sensitization method using quinazolinedione derivatives
US5965695A (en) 1990-05-15 1999-10-12 Chiron Corporation Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such
US5420297A (en) 1990-10-24 1995-05-30 Fujisawa Pharmaceutical Co., Ltd. Peptides having substance P antagonistic activity
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
DE4106101A1 (de) * 1991-02-27 1992-09-03 Bayer Ag Fucose-markierte cytostatika
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
DE4120646A1 (de) 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
DE59209745D1 (de) 1991-11-29 1999-10-21 Hoechst Ag Peptide mit insulinartiger Wirkung
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
AU662434B2 (en) 1992-08-07 1995-08-31 Sankyo Company Limited Peptides capable of inhibiting the activity of HIV protease, their preparation and their use
US5872207A (en) 1992-09-04 1999-02-16 Sanofi Pharmaceuticals, Inc. N-terminal-marked peptides immobilized on glass beads and method of preparation and method of use thereof
IL106998A0 (en) 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5576298A (en) 1992-11-30 1996-11-19 Research And Development Institute, Inc. At Montana State University Peptides from pseudomonas syringae possessing broad-spectrum antibiotic activity
SE9300012D0 (sv) 1993-01-05 1993-01-05 Astra Ab New peptides
US5750648A (en) 1993-08-20 1998-05-12 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
CA2173990A1 (en) * 1993-10-12 1995-04-20 Narasinga Rao A library of glyco-peptides useful for identification of cell adhesion inhibitors
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
US5780589A (en) 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
FR2729668A1 (fr) 1995-01-23 1996-07-26 Adir Nouveaux derives de mercaptoalcanoyldipeptides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5677286A (en) * 1995-04-27 1997-10-14 The University Of Michigan Glycosylated analogs of camptothecin
US6143931A (en) 1997-04-16 2000-11-07 Arqule, Inc. Synthesis and use of α-ketoamide derivatives and arrays

Also Published As

Publication number Publication date
EP0819135B1 (de) 1999-11-17
CZ314397A3 (cs) 1998-01-14
DE59603678D1 (de) 1999-12-23
CN1185786A (zh) 1998-06-24
HUP9800513A2 (hu) 1998-06-29
EE9700258A (et) 1998-04-15
PL183574B1 (pl) 2002-06-28
WO1996031532A1 (de) 1996-10-10
BG101892A (en) 1998-05-29
BG63048B1 (bg) 2001-02-28
CA2217164A1 (en) 1996-10-10
IS1822B (is) 2002-10-01
SK134597A3 (en) 1998-05-06
NO974564L (no) 1997-11-25
BR9604825A (pt) 1999-01-05
JPH11502860A (ja) 1999-03-09
IS4562A (is) 1997-09-18
DE19512484A1 (de) 1996-10-17
EE03619B1 (et) 2002-02-15
KR19980703591A (ko) 1998-11-05
AU713466B2 (en) 1999-12-02
CZ291098B6 (cs) 2002-12-11
RU2170234C2 (ru) 2001-07-10
UA61054C2 (en) 2003-11-17
ES2140078T3 (es) 2000-02-16
NZ305855A (en) 1999-11-29
GR3032605T3 (en) 2000-05-31
EP0819135A1 (de) 1998-01-21
PL322681A1 (en) 1998-02-16
ATE186738T1 (de) 1999-12-15
HUP9800513A3 (en) 1998-09-28
US6271342B1 (en) 2001-08-07
AU5397696A (en) 1996-10-23
NO974564D0 (no) 1997-10-02
DK0819135T3 (da) 2000-05-08
SK281785B6 (sk) 2001-07-10
TW384290B (en) 2000-03-11

Similar Documents

Publication Publication Date Title
MX9707613A (es) Citostaticos modificados con hidratos de carbono.
AU7299796A (en) Cellulases, the genes encoding them and uses thereof
AU6919794A (en) Sustained antiepileptic therapy
EP0638833A3 (en) Display arrangements.
ZA966582B (en) Pesticidal compositions.
EP0676156A4 (en) COMBINED CHAIR.
ZA966676B (en) Bacteriocin.
ZA966916B (en) Insecticidally active composition.
ZA965516B (en) Dialkyl-halogenopheyl-substituted ketoenols.
ZA965292B (en) Enzymatic composition.
EP0646342A3 (en) Chair.
TR199600902A2 (tr) Hücre transfeksiyonu.
ZA931172B (en) Improved simulator arrangement.
EP0657679A3 (en) Connection unit, in particular quick-multiple connection device.
GB2302446B (en) Ovenized crystal assembly.
EP0679076A4 (en) INVISIBLE DRESSING.
ZA961731B (en) Free radical scavengers.
ZA966699B (en) Substituted 2-phenylpyridines.
EP0614293A3 (en) Multiplexer.
AU6896296A (en) Tidal watch
ZA969560B (en) Substituted 1-methyl-3-phenylpyrazoles.
ZA965579B (en) Planters.
GR950200265U (en) Barometric wrist-watch.
GR2001650Y (en) Watch-strap show case with drawers.
AUPM986194A0 (en) The self defence trainer